Document Detail


Dyslipidemia in patients with nonalcoholic fatty liver disease.
MedLine Citation:
PMID:  22418885     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients with nonalcoholic fatty liver disease (NAFLD) often have dyslipidemia along with other features of metabolic syndrome such as obesity, diabetes mellitus, and hypertension. The dyslipidemia in NAFLD is characterized by increased serum triglycerides, increased small, dense low-density lipoprotein (LDL nontype A) particles, and low high-density lipoprotein (HDL) cholesterol. The pathogenesis of dyslipidemia in NAFLD is not well understood, but it is likely related to hepatic overproduction of the very low-density lipoprotein particles and dysregulated clearance of lipoproteins from the circulation. There is unequivocal evidence that cardiovascular disease is the most common cause of mortality in patients with NAFLD. Aggressive treatment of dyslipidemia plays a critical role in the overall management of patients with NAFLD. Statins are the first-line agents to treat high cholesterol and their dosage should be adjusted based on achieving therapeutic targets and tolerability. Although all statins appear to be effective in improving cholesterol levels in patients with NAFLD, there is more experience with atorvastatin in patients with NAFLD; furthermore, it is the only statin to date to show a reduced cardiovascular morbidity in patients with NAFLD. The risk for serious liver injury from statins is quite rare and patients with NAFLD are not at increased risk for statin hepatotoxicity. Omega-3 fatty acids are perhaps the first choice to treat hypertriglyceridemia because of their safety, tolerability, and efficacy in improving serum triglycerides, as well as their potential to improve liver disease.
Authors:
Hemant Chatrath; Raj Vuppalanchi; Naga Chalasani
Related Documents :
12081735 - New insight into bile flow dynamics in anomalous arrangement of the pancreaticobiliary ...
1675695 - Acetaminophen induced pancreatitis.
6712475 - The spectrum of biliary tract obstruction from chronic pancreatitis.
10382785 - Interleukin 1 receptor antagonist and e-selectin concentrations: a comparison in patien...
22622105 - Pictorial interlude: caught up in a 'whirl'.
551765 - Ventilatory function in laryngectomized patients.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2012-03-13
Journal Detail:
Title:  Seminars in liver disease     Volume:  32     ISSN:  1098-8971     ISO Abbreviation:  Semin. Liver Dis.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-03-15     Completed Date:  2012-07-30     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  8110297     Medline TA:  Semin Liver Dis     Country:  United States    
Other Details:
Languages:  eng     Pagination:  22-9     Citation Subset:  IM    
Copyright Information:
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.
Affiliation:
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / etiology
Dyslipidemias / complications*,  therapy*
Fatty Acids, Omega-3 / therapeutic use
Fatty Liver / complications*
Fibric Acids / therapeutic use
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects,  therapeutic use*
Life Style
Grant Support
ID/Acronym/Agency:
K24 DK069290/DK/NIDDK NIH HHS; K24 DK069290A/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Fatty Acids, Omega-3; 0/Fibric Acids; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  NAFLD in the Absence of Metabolic Syndrome: Different Epidemiology, Pathogenetic Mechanisms, Risk Fa...
Next Document:  Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.